NCT00239681

URI: https://gptkb.org/entity/NCT00239681

GPTKB entity

Predicate	Object
gptkbp:instanceOf	gptkb:clinical_trial
gptkbp:ageRange	18 years and older
gptkbp:allocates	Randomized
gptkbp:clinicalTrials.govIdentifier	gptkb:NCT00239681
gptkbp:completedIn	December 2006
gptkbp:condition	gptkb:Metastatic_Breast_Cancer
gptkbp:eligibility	Women with HER2-positive metastatic breast cancer who have received prior therapy including an anthracycline, a taxane, and trastuzumab
gptkbp:enrollment	399
gptkbp:gender	Female
gptkbp:intervention	gptkb:Capecitabine gptkb:Lapatinib
gptkbp:location	gptkb:Asia gptkb:Europe gptkb:United_States
gptkbp:mask	None (Open Label)
gptkbp:period	Phase 3
gptkbp:primaryCompletionDate	December 2006
gptkbp:result	Time to progression
gptkbp:secondaryOutcome	Overall survival Response rate
gptkbp:sponsor	GlaxoSmithKline
gptkbp:startDate	October 2005
gptkbp:studyType	Interventional
gptkbp:title	gptkb:A_Study_of_the_Safety_and_Efficacy_of_Lapatinib_in_Combination_With_Capecitabine_in_Women_With_Metastatic_Breast_Cancer
gptkbp:bfsParent	gptkb:JUPITER_trial
gptkbp:bfsLayer	6
https://www.w3.org/2000/01/rdf-schema#label	NCT00239681